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Abstract The synthetic flavone flavopiridol can be cytostatic or
cytotoxic to mammalian cells, depending on the concentration of
the drug and the duration of exposure. It has been shown to
inhibit the cyclin-dependent kinase (CDK) family of cell cycle
regulatory enzymes. However, the existence of additional
potential targets for drug action remains a matter of interest to
define. To identify cellular targets, flavopiridol was immobilized.
CDKs, particularly CDK 4, bound weakly to immobilized
flavopiridol when ATP was absent but not in its presence. Two
proteins with molecular weights of 40 kDa and 120 kDa had high
affinities to the immobilized flavopiridol independent of the
presence of ATP. They were present in all cell lines analyzed:
cervical (HeLa), prostate and non-small cell lung carcinoma
(NSCLC) cell lines. A 60-kDa protein, which was present only in
NSCLC cells and bound similarly well to immobilized flavopir-
idol, was identified as cytosolic aldehyde dehydrogenase class 1
(ALDH-1). The level of this protein correlated with the
resistance of NSCLC cell lines to cytotoxicity caused by 500
nM flavopiridol but not higher flavopiridol concentrations.
Despite binding to ALDH-1, there was no inhibition of
dehydrogenase activity by flavopiridol concentrations as high
as 20 WM and flavopiridol was not metabolized by ALDH-1. The
results suggest that high cellular levels of ALDH-1 may reduce
cytotoxicity of flavopiridol and contribute to relative resistance
to the drug. This is the first report that flavopiridol binds to
proteins other than CDKs.
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1. Introduction
Recent research in chemotherapeutic development has fo-
cused on drugs targeting signal transduction and cell cycle
proteins, which are often mutated or deregulated in trans-
formed cells. Cyclin-dependent kinases (CDKs) play a central
role in growth regulation as a driving force for cell cycle
progression (for reviews see [1^3]). A few drugs have been
developed which inhibit CDK activity in vitro. Among those
the synthetic £avone £avopiridol is currently in clinical trials
as a potential antitumor agent and has already shown thera-
peutic potential [4,5]. Flavopiridol induces reversible G1 and
G2 phase cell cycle arrest independently of the mutational
status of the tumor suppressor proteins p53 and pRB. This
cytostatic e¡ect was linked to the direct inhibition of various
CDKs [6^9]. CAK (cyclin H/CDK 7), that phosphorylates the
Thr residue of CDKs resulting in kinase activation [10], is also
inhibited by £avopiridol in vitro [11]. This Thr residue is un-
phosphorylated also in £avopiridol-treated cells, indicating in
vivo inhibition of CDK 7 [12]. The binding site for £avopir-
idol has been mapped to the ATP pocket of the CDKs [13].
However, the action of £avopiridol is more complex than can
be explained by CDK inhibition alone. For example, in some
cell types £avopiridol readily induces apoptosis [9,14,15],
while in others it does not [16]. Also transient CDK activation
occurs early after drug treatment correlating likely with loss of
the inhibitory Tyr phosphorylation [8]. At the same time,
cyclin D1 level decreases [8,12]. These observations indicate
that £avopiridol-induced cell cycle arrest may be modulated
by targets in addition to CDKs.
Flavopiridol has shown antiproliferative e¡ects in all tumor
cell lines analyzed so far [11]. However, the sensitivity of
tumor cells to these cytotoxic e¡ects varies. Certain prostate
cancer and homeopoetic cells are the most sensitive [9], while
some small cell lung cancer cell lines, breast cancer cell lines
and bone marrow cells are resistant even up to high levels of
£avopiridol [11]. It is unknown why there are these dramatic
di¡erences in sensitivity to £avopiridol among cell lines. This
variation cannot be simply explained by di¡erent CDK activ-
ities, since cell death can also be observed in £avopiridol-
treated G0/G1 phase endothelial cells, which do not express
active CDKs but not in the NSCLC cell line A549 [14]. The
involvement of commonly known drug resistance proteins
such as the multi-drug resistance P-glycoprotein has also
been excluded [11]. Varying growth rates among cell lines
may explain some of the di¡erences, although £avopiridol
can cause cytotoxic e¡ects on both proliferating and station-
ary phase cells [16]. In some cell lines, the cytotoxicity has
been identi¢ed as apoptosis [9,14,15]. However, cell death of
the NSCLC cell line A549, for example, shows neither typical
apoptotic nor typical necrotic features [16]. It may be possible
that there is more than one mechanism of £avopiridol-di-
rected cell death, which may depend on the cell or tumor type.
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In order to identify proteins, which could potentially mod-
ulate the actions of £avopiridol, we immobilized £avopiridol
and used this reagent as an a⁄nity matrix to isolate proteins
from di¡erent cell lines. One protein was identi¢ed as cyto-
solic aldehyde dehydrogenase class 1 from the NSCLC cell
line A549. Despite its a⁄nity to this enzyme, £avopiridol
does not inhibit the enzymatic activity nor is £avopiridol a
substrate for ALDH-1.
2. Materials and methods
2.1. Cell culture
HeLa cells were grown in RPMI 1640 medium supplemented with
10% fetal bovine serum (FBS) and antibiotics (Gibco). Human non-
small cell carcinoma cell lines (NSCLC) H23, HOP62, H460 and A549
were obtained from NCI Repository, Frederick, MD, USA. Cells
were maintained in RPMI 1640 medium supplemented with 5%
FBS, 2 mM glutamine, 100 units/ml penicillin and 100 Wg/ml strepto-
mycin. All cultures were maintained at 37‡C in a 5% CO2 incubator.
For a⁄nity chromatography experiments cells were harvested with
Trypsin centrifuged and washed twice with phosphate bu¡ered saline
(PBS) and stored in a freezer at 380‡C until use.
2.2. Colony-forming growth assay
Exponentially growing cells (5U105) were treated with graded con-
centrations of £avopiridol for 4 h and 24 h. Following drug treatment,
cells were washed with serum free RPMI 1640 and trypsinized. Ali-
quots containing 250 (H460, A549) or 500 (HOP62, H23) cells were
plated in triplicates in 6-well plates containing 4 ml medium. Plates
were incubated for additional 7 days (H460, A549) or 10 days
(HOP62, H23) in a CO2 incubator. The resulting colonies were then
washed with PBS, ¢xed with methanol, stained with trypan blue
(0.04%), and were counted manually. Vehicle-treated control plates
typically contained 150^200 colonies (HOP62, H23) or 250^400 colo-
nies (H460 and A549). Cloning e⁄ciency of vehicle-treated control
cells were 42% for H23, 33% for HOP62, 50% for H460 and 74%
for A549.
2.3. A⁄nity chromatography
The £avopiridol a⁄nity resin was synthesized as follows: 0.33 g
epoxy-activated Sepharose 6B (Pharmacia, equivalent to about 1 ml
swollen resin) was washed according to the manufacturer’s protocol.
The resin was added to 5 ml 0.1 M NaHCO3 (pH 10.5) containing
6 WMol £avopiridol and incubated at 37‡C for 24 h. The soluble
concentration of £avopiridol was determined at 260 nm in a photo-
meter before and after the coupling procedure. 87% £avopiridol was
coupled corresponding to 5.25 WMol per ml resin. To block unreacted
groups, the resin was incubated for 4 h with 1 M ethanolamine. We
expect that £avopiridol is linked to the resin via the hydroxyl groups.
For chromatography experiments, cells were lysed in 3 ml of lysis
bu¡er (50 mM Tris/HCl (pH 7.5), 250 mM NaCl, 0.1% NP40, 5 mM
EDTA, 50 mM NaF) per 1 ml of packed cells (about 1U108 cells).
Protease inhibitors were added in concentration of 1 mM for phenyl-
methyl-sulfonyl-£uoride, 25 Wg/ml for aprotinin and 25 Wg/ml for
leupeptin. The cells were lysed in a homogenizer or by pipetting
through a 26-gauge size needle. The suspension was centrifuged for
10 min at 15 000 rpm in a SS34 rotor in a Sorvall centrifuge. The
protein amount of the supernatant was determined with a Bradford
protein determination assay (Biorad). The cell extract was diluted with
equal volume of binding bu¡er (20 mM Tris/HCl (pH 8.0), 250 mM
NaCl, 5 mM MgCl2). 1.5 ml of this cell extract was passed over a 1 ml
£avopiridol a⁄nity resin. The resin was washed with 16 column vol-
umes binding bu¡er. Bound proteins were eluted with either a satu-
rated solution of £avopiridol in binding bu¡er (Note: £avopiridol has
low solubility in H2O) or with dimethyl formamide (DMF) concen-
trations up to 20% in binding bu¡er. Proteins were concentrated by
precipitation in 10% trichloro acetic acid and centrifugation. The pro-
tein pellets were washed with acetone. Proteins were analyzed by SDS-
PAGE [17].
2.4. Preparation of proteins for mass spectral analysis
Approximately 20 pmoles of the a⁄nity-puri¢ed p60 protein was
precipitated with 5% TCA and washed twice with acetone (320‡C).
The protein was dissolved in 20 ml 10 mM Tris/HCl (pH 8.2) with
1 mM BME. After 1 h, iodoacetamide was added at a ¢nal concen-
tration of 3 mM. After 30 min at 30‡C, BME was added to 6 mM.
The pH was raised to pH 8.6 with Tris (30 mM), 100 ng Trypsin
(modi¢ed sequencing grade, Boehringer Mannheim) added, and diges-
tion carried out at 37‡C for 12 h. Peptides were separated on a Mi-
chron HPLC with a microbore reverse phase column and analyzed by
MS/MS on a Finnigan MAT LCQ. The MS/MS data was analyzed by
‘Sequest’ software based on a FASTA Swiss Protein database and
individual tryptic peptides matches with predicted fragmentation pat-
terns of y (C-terminal) and b (N-terminal) ions.
2.5. ALDH-1 enzyme assays
For ALDH-1 enzyme assays either puri¢ed or partially puri¢ed
ALDH-1 was used. For ALDH-1 puri¢cation, 2 ml of packed A549
cells were lysed as described and cell extract was passed over £avopir-
idol a⁄nity columns. ALDH-1 was eluted with 20% DMF in binding
bu¡er and BME was added to a ¢nal concentration of 10 mM. The
e¥uents were concentrated by centrifugation in concentrators (FIL-
TRON) with 30 kDa molecular weight cut o¡. The ¢nal volume was
0.2 ml. The proteins were further separated by FPLC using a Super-
ose 12 column. Partially puri¢ed ALDH-1 was prepared as described
using 100 000Ug supernatant [18]. The enzyme assays were carried
out as described [18]. Flavopiridol, dissolved in DMF, was added to
test inhibition of ALDH-1. The highest DMF concentration in the
assay was 2%, which did not have any e¡ect on the enzyme activity.
2.6. Determination of £avopiridol concentration following incubation
with ALDH-1
To test the modi¢cation of £avopiridol by ALDH-1, £avopiridol
was incubated with ALDH-1 as described above and the £avopiridol
concentration was determined as described [19]. Brie£y, £avopiridol
was isolated from the samples, following alkalinization, by extraction
with t-butylmethyl ether. The extract was evaporated; the residue was
reconstituted in mobile phase and analyzed by reversed phase HPLC
using electrochemical detection. All samples were analyzed in dupli-
cate. Samples, whose duplicate determinations did not agree within
10%, were reanalyzed until acceptable reproducibility was obtained.
2.7. Immunoblot analysis
Anti-CDK 1 (CDC 2) antibodies have been described [20]. Anti-
CDK 2, 4 and 7 antibodies were purchased from Santa Cruz Biotech-
nology. Polyclonal anti-ALDH-1 antibodies were prepared by ‘Gen-
emed’ against the unique peptide (C)SSSGTPDLPVLLTDL-COOH.
The immunoblot analysis was carried out as described [21].
3. Results
One possible approach to identify in vivo drug targets is to
isolate proteins with the highest a⁄nity to these drugs using
a⁄nity chromatography. Flavopiridol has two hydroxyl
groups, which are chemically reactive. In a typical experiment,
about 5 WMols £avopiridol were coupled to 1 ml of Sepharose
6B. For chromatography experiments, HeLa cell extract was
prepared in lysis bu¡er and diluted with binding bu¡er con-
taining 0.5 M NaCl, to eliminate unspeci¢c salt-sensitive bind-
ing of proteins to the a⁄nity resin. Elution was done either
with a saturated £avopiridol solution in bu¡er or with increas-
ing amount of organic solvent such as dimethyl formamide
(DMF) or dimethyl sulfoxide (DMSO). The eluted proteins
were concentrated and then separated by SDS-PAGE. In
HeLa cells the most prominent band after staining the gel
with silver nitrate corresponded to a 120-kDa protein fol-
lowed by a 40-kDa and a 28-kDa protein (Fig. 1). While all
proteins were in the same fractions when eluted with £avopir-
idol (Fig. 1A), they were eluted stepwise with increasing
amounts of DMF (Fig. 1B). This is strong evidence for spe-
ci¢c binding of these proteins to the resin-bound £avopiridol.
There were some background bands, but these could be deg-
radation products of the 120-kDa protein.
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Flavopiridol inhibits CDKs’ activity in vitro and the bind-
ing site has been determined to be the ATP pocket of these
kinases [11,13]. We tested the presence of CDK 1, 2, 4 and 7
in wash and e¥uent fractions by immunoblot with the corre-
sponding antibodies after separation of proteins by SDS-
PAGE (Fig. 2, upper panel). CDK 1 was detected only in
the £ow through and the ¢rst wash fraction. CDK 2, 4 and
7 were also detected in further wash fractions. Unlike the 40-
and 120-kDa proteins, the CDKs were not signi¢cantly re-
tarded by the column. This result indicated that the CDKs
do not bind tightly to the immobilized £avopiridol under
these conditions. It is likely for steric reasons that the cou-
pling of £avopiridol to Sepharose 6B blocks or partially
blocks the binding site for CDKs, since the crystal structure
of £avopiridol bound to CDK 2 suggests contact of one of the
-OH residues with the enzyme [13]. Alternatively it is also
possible that high levels of ATP in the cell extract compete
with £avopiridol for binding to CDKs. To test this, we added
apyrase to the HeLa cell extract to degrade ATP. When the
binding of CDKs to the column was analyzed, we found that
CDK 1, 2 and 4 were much more retarded by the £avopiridol
resin than in the presence of ATP (Fig. 2, lower panel). A
small fraction of CDK 4 was found in the 20% DMF e¥uent.
This result con¢rms previous ¢ndings that £avopiridol binds
to the ATP pocket of CDKs [13]. However, ATP easily ab-
rogates this binding. The binding of the 28-, 40- and 120-kDa
proteins was not a¡ected whether ATP was present or not.
NSCLC cell lines, in particular the A549 cell line, are
among those which are rather resistant to the cytotoxic e¡ect
of £avopiridol [11,14]. A⁄nity chromatography with cell ex-
tract from the A549 cell line using the £avopiridol a⁄nity
column showed that in addition to the 40- and 120-kDa pro-
teins there was a protein of about 60 kDa present (Fig. 3).
Because of its abundance and possible involvement in £avo-
piridol resistance, p60 was further puri¢ed by HPLC. The
mass of a total of 25 peptides was determined after Trypsin
digestion of the protein by ion trap mass spectroscopy anal-
ysis. The masses and spectra of all peptides showed a match
with a single protein, which was identi¢ed as cytosolic alde-
hyde dehydrogenase class 1 (ALDH-1). The ALDH family of
proteins functions in metabolism of aldehydes to protect cells
from their toxicity [22^24]. Multiple ALDH isoforms have
been characterized and have di¡erent substrate speci¢city.
They have been classi¢ed according to their amino acid se-
quence homology as ALDH-1 (cytosolic), ALDH-2 (mito-
chondrial) and ALDH-3 (cytosolic and mitochondrial).
Among four NSCLC cell lines, A549 was found to be more
resistant to cell death by £avopiridol compared to three other
cell lines despite the fact that cell death in NSCLC cell lines is
independent from the expression of bcl-2 [25]. This is also
Fig. 1. A⁄nity chromatography with £avopiridol as ligand. A: Elu-
tion with £avopiridol. Lane 1, last bu¡er wash; lanes 2^5, 1 ml sat-
urated £avopiridol each. B: Elution with DMF; lane 1, 10% DMF;
lanes 2^3, 20% DMF. The proteins were separated by SDS-PAGE
and stained with silver nitrate.
Fig. 2. Immunoblots of proteins from £avopiridol a⁄nity chroma-
tography with anti-CDK antibodies. Upper panel: The chromatog-
raphy was performed as described in Fig. 1B except that the washes
were collected in ten 1 ml wash fractions. The £ow through, the
¢rst and second washes were not concentrated. All other fractions
were concentrated by TCA precipitation. Lower panel: The chroma-
tography was performed as in the upper panel, except that the cell
extract was incubated with 5 Wg/ml apyrase for 1 h. To, total cell
extract; FT, £ow through; lanes 1^10, washes.
Fig. 3. Proteins bound to immobilized £avopiridol from A549. The
chromatography conditions are as in Fig. 1. Elution was done with
10 and 20% DMF. The concentrated proteins were separated by
SDS-PAGE and stained with Coomassie blue.
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shown by a colony-forming assay (Fig. 4). Flavopiridol dimin-
ished the colony-forming ability of the lung cancer cell lines
after 24 h but not 4 h of drug exposure (Fig. 4A). H23 and
HOP62 were most sensitive, with colony counts reduced to
13 and 0.9% of control; H460 was less sensitive and A549
most resistant, with 34% and 72% of control colony number
after exposure to 500 nM £avopiridol for 24 h. We deter-
mined the ALDH-1 levels in the four cell lines by immuno-
blots with anti-ALDH-1 antibodies and as control with anti-
CDK 2 antibodies (Fig. 4B). A549 cells had the highest con-
centration of ALDH-1 followed by H460. H23 and HOP62
had undetectable levels of ALDH-1 compared to these two
cell lines. The ALDH activities including ALDH-1 had been
determined in the 60 cell lines from the NCI drug screen and
the relative ALDH-1 activities of the four NSCLC cell lines
are: H23 and HOP626H4606A549, which correlates with
the colony formation assay and the immunoblot data [26]. We
analyzed if the ALDH-1 level was a¡ected in A549 cells upon
£avopiridol treatment, but the level was not changed (data
not shown). Although we ¢nd correlation of ALDH-1 content
(level and activity) with the colony formation assay, the re-
sults indicate that there must be additional mechanisms,
which interfere with £avopiridol resistance at higher £avopir-
idol concentrations than 500 nM.
Next we investigated whether £avopiridol inhibits ALDH-1
enzyme activity. We used either partially puri¢ed ALDH-1
(100 000Ug fraction) [18], or a⁄nity-puri¢ed ALDH-1, which
was puri¢ed further by Superose 12 column chromatography.
ALDH-1 activity (enzyme kinetics) was tested alone or in the
presence of £avopiridol; however, there was no inhibition of
the ALDH-1 activity. The enzyme activity was determined as
1.53U1034 Mol NAD reduced/min/mg protein in the ab-
sence or presence of 20 WM £avopiridol in enzyme assays
using partially puri¢ed ALDH-1. When puri¢ed ALDH-1
was used, the activity was determined as 5.4U1033 Mol
NAD reduced/min/mg protein in the absence or presence
of 10 WM £avopiridol. Due to solubility problems we did
not use higher £avopiridol concentrations. Similarly, reducing
the substrate (propionaldehyde) concentration 3^10-fold or
cofactor (NAD) concentration up to 15-fold without chang-
ing the drug concentrations did not result in increased inhibi-
tion of ALDH-1 by £avopiridol either (data not shown).
Thus, £avopiridol binds to ALDH-1 without a¡ecting its ac-
tivity. We also tested if £avopiridol is a substrate for ALDH-
1. Flavopiridol was incubated for up to 1 h with puri¢ed
ALDH-1 in the absence and presence of NAD. However,
no change in the concentration of £avopiridol was observed.
Thus £avopiridol is not a substrate for ALDH-1.
4. Discussion
We have isolated several £avopiridol interacting proteins.
Fig. 4. Correlation of cytotoxicity of £avopiridol on NSCLC cells with ALDH-1 level. A: Colony-forming assay: cells were exposed to £avo-
piridol (100, 500, or 1000 nM) or vehicle for 4 h (open bar) or 24 h (hatched bar). Colonies formed after drug removal were enumerated as de-
scribed in Section 2. Values are means þ S.E.M. of three experiments. B: Immunoblot with anti-ALDH-1 antibodies and as control with anti-
CDK 2 antibodies.
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We expected to ¢nd CDKs among the binding proteins, be-
cause their enzymatic activities were reported to be inhibited
by £avopiridol in vitro with IC50 values of 200^400 nM and
£avopiridol was shown to bind to the ATP pocket of CDK 2
[13]. CDKs showed indeed a certain a⁄nity for the immobi-
lized £avopiridol but only when the ATP in the cell extract
was degraded con¢rming that ATP competes with £avopiridol
for binding to CDKs. The question arises whether these bind-
ing conditions also re£ect the in vivo binding of £avopiridol
to CDKs, since the intracellular ATP concentration is around
5 mM. Our results suggest that £avopiridol has higher a⁄nity
to the 28-, 40- and 120-kDa proteins and to ALDH-1, which
are retarded on the column throughout all the wash steps
independent of ATP, than to CDKs.
One of the proteins we identi¢ed was ALDH-1, which was
present only in NSCLC cell lines but not in the other two cell
lines tested. In enzyme assays we found that ALDH-1 is not
inhibited by £avopiridol concentrations up to 20 WM. This
would indicate that £avopiridol binds to a unique site on
ALDH-1, which is not important for its enzymatic activity.
We could further exclude the possibility that ALDH-1 modi-
¢es £avopiridol. There are di¡erences in the cytotoxicity of
£avopiridol among NSCLC cell lines, which contain ALDH-
1, and our results suggest that ALDH-1 may contribute to
this. High cellular ALDH-1 levels could bind a considerable
amount of £avopiridol in the cytosol and change the sensitiv-
ity level of cells to £avopiridol. Since £avopiridol has cyto-
static and cytotoxic e¡ects on all cell lines independent of the
cell type, binding of £avopiridol to ALDH-1 is, however, un-
likely to be the only cause for these e¡ects. A screen of the 60
cell lines used by the NCI in its Developmental Therapeutics
Program to test new drugs for the presence of ALDH-1 has
shown that NSCLC cell lines have the highest levels of this
enzyme [26]. It would be interesting and important to test
CDK inhibitors unable to bind to ALDH-1, which might be
more useful anticancer agents, owing to their not binding to
other cellular components.
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